Barclays Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,065.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price trimmed by Barclays from $1,080.00 to $1,065.00 in a research note issued to investors on Friday, Benzinga reports. The firm currently has an overweight rating on the biopharmaceutical company’s stock.

A number of other brokerages have also weighed in on REGN. Truist Financial reduced their price target on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a research note on Friday. Piper Sandler cut their target price on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research note on Friday. Cantor Fitzgerald restated a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. TD Cowen upped their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $1,260.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, October 22nd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,090.24.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded up $5.40 on Friday, hitting $843.60. The stock had a trading volume of 1,087,285 shares, compared to its average volume of 768,492. Regeneron Pharmaceuticals has a one year low of $783.57 and a one year high of $1,211.20. The company has a quick ratio of 4.62, a current ratio of 5.99 and a debt-to-equity ratio of 0.09. The stock has a market cap of $93.00 billion, a price-to-earnings ratio of 20.88, a P/E/G ratio of 2.88 and a beta of 0.15. The company’s 50-day moving average is $1,058.43 and its two-hundred day moving average is $1,038.87.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping the consensus estimate of $8.93 by $2.63. The firm had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. Regeneron Pharmaceuticals’s quarterly revenue was up 12.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $8.79 EPS. On average, analysts expect that Regeneron Pharmaceuticals will post 37.46 earnings per share for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In other news, VP Jason Pitofsky sold 487 shares of the stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the transaction, the vice president now owns 4,204 shares in the company, valued at $4,498,280. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, VP Jason Pitofsky sold 487 shares of the stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the transaction, the vice president now owns 4,204 shares in the company, valued at $4,498,280. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is currently owned by company insiders.

Institutional Trading of Regeneron Pharmaceuticals

Several large investors have recently modified their holdings of REGN. Vanguard Group Inc. boosted its holdings in Regeneron Pharmaceuticals by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock valued at $8,595,268,000 after purchasing an additional 91,956 shares during the period. Capital International Investors boosted its holdings in Regeneron Pharmaceuticals by 7.3% in the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after purchasing an additional 213,038 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Regeneron Pharmaceuticals by 25.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after purchasing an additional 184,561 shares during the period. International Assets Investment Management LLC boosted its holdings in Regeneron Pharmaceuticals by 86,013.3% in the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after purchasing an additional 879,916 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its holdings in Regeneron Pharmaceuticals by 12.4% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company’s stock valued at $567,864,000 after purchasing an additional 59,769 shares during the period. 83.31% of the stock is owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.